Abeona Therapeutics, Inc. (ABEO)
5.92
-0.12
(-1.99%)
USD |
NASDAQ |
Aug 28, 16:00
5.98
+0.06
(+1.01%)
After-Hours: 20:00
Abeona Therapeutics Free Cash Flow : -81.53M for June 30, 2026
Free Cash Flow Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2026 | -81.53M |
| March 31, 2026 | -85.24M |
| December 31, 2025 | -84.30M |
| September 30, 2025 | -82.36M |
| June 30, 2025 | -71.29M |
| March 31, 2025 | -63.00M |
| December 31, 2024 | -58.46M |
| September 30, 2024 | -50.72M |
| June 30, 2024 | -43.87M |
| March 31, 2024 | -40.79M |
| December 31, 2023 | -37.49M |
| September 30, 2023 | -42.08M |
| June 30, 2023 | -43.09M |
| March 31, 2023 | -41.78M |
| December 31, 2022 | -43.61M |
| September 30, 2022 | -63.10M |
| June 30, 2022 | -67.04M |
| March 31, 2022 | -69.58M |
| December 31, 2021 | -69.82M |
| September 30, 2021 | -37.95M |
| June 30, 2021 | -38.19M |
| March 31, 2021 | -36.67M |
| December 31, 2020 | -36.36M |
| September 30, 2020 | -49.08M |
| June 30, 2020 | -57.30M |
| Date | Value |
|---|---|
| March 31, 2020 | -66.74M |
| December 31, 2019 | -69.33M |
| September 30, 2019 | |
| June 30, 2019 | |
| March 31, 2019 | |
| September 30, 2018 | -36.75M |
| June 30, 2018 | -32.90M |
| March 31, 2018 | -25.45M |
| December 31, 2017 | -23.80M |
| September 30, 2017 | -21.18M |
| June 30, 2017 | -18.47M |
| March 31, 2017 | -16.72M |
| December 31, 2016 | -13.53M |
| September 30, 2016 | -13.27M |
| June 30, 2016 | -11.67M |
| March 31, 2016 | -10.30M |
| December 31, 2015 | -10.73M |
| September 30, 2015 | -8.689M |
| June 30, 2015 | -6.29M |
| March 31, 2015 | -4.658M |
| December 31, 2014 | -1.611M |
| September 30, 2014 | -0.984M |
| June 30, 2014 | -1.761M |
| March 31, 2014 | 0.22M |
| December 31, 2013 | -0.001M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Forum Markets, Inc. | -318.80M |
| Corcept Therapeutics, Inc. | 106.92M |
| ACADIA Pharmaceuticals, Inc. | 145.62M |
| Alnylam Pharmaceuticals, Inc. | 793.94M |
| Anika Therapeutics, Inc. | 0.562M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -17.50M |
| Cash from Investing (Quarterly) | 15.69M |
| Cash from Financing (Quarterly) | -3.335M |
| Free Cash Flow Per Share (Quarterly) | -0.3151 |
| Free Cash Flow to Equity (Quarterly) | -14.67M |
| Free Cash Flow to Firm (Quarterly) | -17.28M |
| Free Cash Flow Yield | -24.71% |